Pharmacogenomics is the study of how an individual's genetic inheritance affects the body's response to drugs. This report provides information on patient's genotype response to a list of drugs (with evidence level 1A to 3) based on the guidelines developed by databases such as Pharmacogenomics Knowledge Base (PharmGKB), Clinical Pharmacogenetics Implementation Consortium (CPIC), US Food and Drug Administration (FDA), Dutch Pharmacogenetics Working Group (DPWG) and Pharmacogene Variation Consortium (PharmVar).

The determination of genotype is obtained using an in-house pipeline which combines the two top-ranked star alleles from the haplotypes for the concerned genes from the patient data. The genotype to diplotype [star (*) allele or HGVS nomenclature and phenotype prediction, depends on the gene mapping defined by PharmGKB, CPIC and the enzyme activity known as the activity score of the alleles. The phenotypes follow CPIC’s proposed standard nomenclature.

The mapping of phenotypes to drugs, dosages, interpretation, and recommendations are obtained from the CPIC, FDA, PharmGKB or DPWG guideline publications.